Your Messages Inbox
Your Article Summary
See Latest ArticlesPivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet
Gilead, 09/14/09
Gilead Sciences, Inc. announced the publication of data from DAR–311 (DORADO), a Phase III clinical trial evaluating the company’s once–daily oral endothelin receptor antagonist darusentan as an add–on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three drug antihypertensive regimen that includes a diuretic.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor